Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant EGFR-ADC plus PD-1 inhibitor in stage IV oral squamous cell carcinoma
ChiCTR2600122511Phase 4Recruiting
- Sponsor
- Peking University School of Stomatology
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of vibetocotumab and pucotenlimab in Oral Mucosal Carcinoma, sponsored by Peking University School of Stomatology. Primary endpoint: Major pathological response rate. Started Mar 2026; status: recruiting.
02
Drugs
vibetocotumabpucotenlimab
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2600122511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122511.